OPTN/SRTR 2024 Annual Data Report: Pancreas

Raja Kandaswamy^1,2, Peter G. Stock^1,3, Jonathan M. Miller^1,4, Stryker-Ann Vosteen⁵, Dzhuliyana Handarova⁵, Jon J. Snyder^1,4,6, Allyson Hart^1,4

¹Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, MN

²Department of Surgery, University of Minnesota, Minneapolis, MN

³Department of Surgery, University of California San Francisco, San Francisco, CA

⁴Department of Medicine, Hennepin Healthcare, University of Minnesota, Minneapolis, MN

⁵Organ Procurement and Transplantation Network, United Network for Organ Sharing, Richmond, VA

⁶Department of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

Abstract

In 2024, the overall number of adult pancreas transplants in the United States decreased to 821, an 8.0% drop from the prior year, predominantly driven by a decline in simultaneous pancreas-kidney (SPK) transplants. However, adult waitlist additions increased in SPK to 1,661 in 2024 from 1,585 in 2023. Adult transplant rates have declined steadily since 2019 to a low of 30.1 transplants per 100 patient-years in 2024. The proportion of candidates with type 2 diabetes on the waiting list was stable at 25.7% in 2024. Waiting time for adult SPK transplants continued to be relatively short, with only 23.2% of candidates on the waiting list at the end of 2024 having been waiting 2 years or more. Pretransplant mortality on the waiting list decreased to 4.5% in 2024, from 6.2% in 2020. The overall pancreas donor counts (adult and pediatric) have dropped to 1,131 in 2024 from 1,346 in 2013. Less than 10% of the donors were aged 40 years or older. While head trauma as a cause of death in pancreas donors remained lower in 2024 than a decade ago, anoxia as a cause of death started to stagnate beginning in 2022. Of the pancreata recovered for transplant in 2024, 25.1% were not transplanted. Outcomes after pancreas transplant in adults remained strong with only 9.4% graft loss in the first year following SPK transplant in 2023. Long-term death-censored kidney graft failure in SPK was low at 1.9%, 8.5%, and 15.9% at 1, 5, and 10 years, respectively. Mortality at 10 years posttransplant has also improved to 27.5%, 13.1%, and 20.6% for pancreas-after-kidney transplant, pancreas transplant alone, and SPK transplant, respectively.

Keywords: Pancreas transplant, transplant outcomes, waitlist outcomes

1 Introduction

There has been an overall trend of decreasing numbers of pancreas transplants in the United States since 2019. There was a sharp drop in simultaneous pancreas-kidney (SPK) transplants in 2024. This has contributed to a decrease in transplant rates, now at 30.0 transplants per 100 patient-years waiting for adults, and possibly indicates that centers have become more selective in their criteria for transplant. Meanwhile, the number of adult waitlist additions increased in 2024.

Expanding the donor pool with increased utilization of donation after circulatory death (DCD) donors might help to improve transplant rates. It remains to be seen if the use of normothermic regional perfusion will increase utilization of pancreata from DCD donors.

The steady increase from 2013 to 2021 of waitlist additions and transplants in adults with type 2 diabetes seems to have plateaued, with 25.7% of transplants being performed in this group in 2024. This is despite several studies showing that intermediate-term outcomes of pancreas graft survival are comparable between recipients with type 1 diabetes and recipients with type 2 diabetes.¹

Overall, outcomes in adults (which constitute 96.9% of pancreas transplant recipients in 2024 and are the focus of this chapter) continue to show low technical failures and graft rejection. The bar continues to be raised for pancreas transplant outcomes due to the development of highly effective medical management strategies.

Since fall 2024, the Organ Procurement and Transplantation Network (OPTN) Pancreas Transplantation Committee (the Committee) has been dedicated to refining and advancing the continuous distribution framework for pancreas allocation. Upon receiving the Scientific Registry of Transplant Recipients (SRTR) modeling report, which aimed to assess the feasibility of modeling nonuse and nonutilization of pancreata, the Committee was advised that current data limitations preclude effective modeling of the requested parameters. Moreover, modeling pancreas allocation more broadly may not be the most appropriate approach.

In response, the OPTN contractor developed a tailored dashboard to support the Committee’s efforts in conducting match-run analyses using the attributes previously identified. This dashboard was intended to assist the Committee in determining final attribute weights for the continuous distribution framework.

As part of the winter 2025 public comment cycle, the Committee released an update that included the SRTR modeling report and outlined progress on the development of a pancreas medical urgency attribute. This work involved extensive research and consultation with endocrinology experts to finalize the criteria for medical urgency in pancreas transplantation.

Following a directive from the Health Resources and Services Administration (HRSA) issued on July 2, 2025, the Committee was instructed to pause work on continuous distribution in light of concerns related to allocation out of sequence and the development of policies to address such allocation. The Committee is now pivoting to explore new initiatives that address critical challenges in pancreas transplantation, including patient access and the optimization of procurement and placement processes.

2 Waiting List

The number of new adult candidates added to the waiting list increased in 2024 compared with 2023 in SPK (1,661 versus 1,585) and decreased in the pancreas transplant alone (PTA; 165 versus 180) and pancreas-after-kidney (PAK) transplant (109 versus 111) categories. This is in keeping with the trend since 2013 where SPK listing has increased by 31.2% and PTA and PAK listings have decreased by 35.3% and 37.4%, respectively (Figure PA 1).

Prevalent adult candidate listings have followed the same pattern between 2013 and 2024, with an 8.6% increase in SPK and 19.5% and 51.9% decreases in PTA and PAK, respectively (Figure PA 2). The age distribution of candidates on the waiting list has had a slight shift toward those aged 35-44 years, and away from those aged 45-54 years, between 2013 and 2024. The proportions of those aged 18-34 years and those aged 55 years or older were largely unchanged (Figure PA 3). The female-male ratio on the waiting list for any pancreas transplant type has been stable since 2013, and the percentages were 45.4% female and 54.6% male in 2024 (Figure PA 4). However, in the PTA category, the ratio was reversed with 45.4% male and 54.6% female in 2024 (Table PA 1). In terms of the racial and ethnic distribution of the waiting list, there has been a continual decrease of White candidates during that period: down to 44.2% in 2024 compared with 65.8% in 2013. There has been an associated increase in all other groups, with Black candidates making up the second largest percentage of the waiting list in 2024 at 28.5%, followed by Hispanic candidates at 19.2% (Figure PA 5). At the end of 2024, the proportion of Black candidates was highest on the SPK list at 31.0%, compared with PAK (22.5%) and PTA (17.1%) (Table PA 1). The proportion of candidates with type 2 diabetes had been increasing since 2015 and plateaued in 2024 at 25.6% of listings, compared with 25.2% in 2023 (Figure PA 6). The highest proportion of candidates with type 2 diabetes in 2024 was on the SPK waiting list at 28.3% (Table PA 2).

Waiting time has generally decreased overall, with the proportion of adult candidates waiting 2 years or longer down to 26.6% in 2024 compared to 34.6% in 2013 (Figure PA 7). This was largely driven by shorter SPK waiting times, with only 23.2% of candidates at the end of 2024 having been on the waiting list for 2 years or longer, compared to 43.5% of PAK candidates and 40.1% of PTA candidates (Table PA 3). Following a steady increase in candidates with obesity (body mass index [BMI] > 30) from 2017 to 2021, the BMI distribution on the waiting list stabilized at 23.6% candidates with obesity in 2024, largely unchanged from 2023 (Figure PA 8). The distribution of the waiting list by blood type was largely unchanged in 2024, with candidates with blood type O making up the largest group (48.7%) (Figure PA 9). The distribution of candidates by intended transplant type shows that SPK listings continued to increase and, for the first time in the past decade, made up over 80% of prevalent listings in 2024. There has been a corresponding decrease in PAK and PTA listings over the past decade, which was most pronounced in the PAK category: from 15.8% of candidates in 2013 to 8.0% of candidates in 2024 (Figure PA 10). The proportion of pancreas retransplant candidates also continued to decline and was 5.8% in 2024 compared with 15.5% in 2013 (Figure PA 11). Unsurprisingly, retransplant listings were highest in the PAK category, at 18.6% in 2024, compared with 9.5% of PTA and 3.4% of SPK listings (Table PA 3). The proportion of active versus inactive candidates on the waiting list has been stable since 2020. It is concerning, however, that nearly one-half of all candidates were inactive in 2024, though this level of inactivity has been relatively constant since 2013. Reasons for this high proportion are unclear and may warrant further examination by the Committee (Figure PA 12).

Overall transplant rates have decreased over the latest 5 years of data: 30.1 transplants per 100 patient-years in 2024 for deceased donor transplants, down from 44.8 in 2019. While the initial period of decline was attributed to the COVID-19 pandemic, the continued postpandemic drop is notable (Figure PA 13). This downturn in transplant rates was most pronounced for candidates with type 2 diabetes, at 32.8 transplants per 100 patient-years in 2024 compared with a recent peak of 58.4 in 2019—perhaps indicating a softening of the enthusiasm for transplant for patients with type 2 diabetes (Figure PA 14). This downturn is also evident from the sharp decrease in deceased donor transplant rates for SPK candidates: 34.5 transplants per 100 patient-years in 2024 compared with 54.3 in 2019. In addition to postpandemic declines in SPK deceased donor transplant rates, deceased donor transplant rates for PTA candidates have shown consistent decline over the past decade: 15.7 transplants per 100 patient-years in 2024 compared with 33.2 in 2013 (Figure PA 16). There were no considerable differences across blood types relating to the postpandemic decline in transplant rates (Figure PA 15).

For 3-year outcomes on the waiting list for adult SPK candidates newly listed in 2019-2021, 58.6% of candidates underwent deceased donor transplant, 19.7% were removed from the list for reasons other than transplant or death, and 12.0% were still waiting. In addition, 4.3% of these SPK candidates received a living donor transplant (presumably kidney) and 5.4% died on the waiting list (Figure PA 19). This is in contrast to the PAK list, where only 29.3% received deceased donor transplant and 39.7% were removed from the list for reasons other than transplant or death (Figure PA 17). In the PTA group, 42.3% received a deceased donor transplant and 31.0% were removed from the list for reasons other than transplant or death (Figure PA 18).

Adult pretransplant mortality on the waiting list has been decreasing and was 4.5 deaths per 100 patient-years in 2024, down from a recent high of 6.2 in 2020 (Figure PA 20). There are no notable trends for pretransplant mortality rates in recent years in terms of age (Figure PA 21) or racial and ethnic distribution (Figure PA 22). Male candidates had a marginally higher pretransplant mortality rate in 2024 of 4.9 deaths per 100 patient-years compared to female candidates at 4.0 (Figure PA 23). The decrease in pretransplant mortality was primarily driven by PAK and SPK candidates, whose rates were 1.0 and 5.1 deaths per 100 patient-years in 2024, down from 3.6 and 7.1 in 2020, respectively (Figure PA 24). Pretransplant mortality rates by geographical area showed no discernable pattern in 2024, with a wide variation from 0 to 25.8 deaths per 100 patient-years (Figure PA 25).

Mortality within 6 months after removal from the waiting list had steadily increased from 2019 to 2022, when it reached 8.0%, then declined in the postpandemic era to 5.4% in 2024 (Figure PA 26). This mortality within 6 months of waitlist removal was highest in the SPK group, as expected, at 7.6% in 2024 (Figure PA 28). There was no notable pattern in mortality within 6 months of waitlist removal across age categories (Figure PA 27).

3 Transplants

The downward trend in the total number of adult pancreas transplants performed in the United States continued in 2024 with a decrease to 821, down from 892 in 2023. This represents an overall 17.4% decrease in the number of adult pancreas transplants from 2013 (Figure PA 29). Although the decrease in the number of adult pancreas transplants performed in 2024 compared to 2023 was almost all in the category of SPK transplant, the number of PTA and PAK transplants decreased by 64.6% and 55.1%, respectively, since 2013 (Figure PA 30). The declines in the number of pancreas transplants were seen in all age groups (Figure PA 31) and in both sexes (Figure PA 32). The disparity by sex has not changed appreciably over the past decade; there were 474 total adult pancreas transplants performed in male candidates and 347 in female candidates in 2024.

The most significant decreases in adult pancreas transplant numbers from 2023 to 2024 occurred in White and Black recipients, with relative stability in the small numbers of Hispanic, Asian, Native American, and Multiracial recipients. Racial and ethnic information was unreported in seven recipients in 2024. Despite the decrease in the number of Black recipients to 255 in 2024 from 293 in 2023, the number of Black recipients has increased by 44.1% over roughly the past decade, from 177 in 2013 (Figure PA 33). That increase in the number of Black recipients correlates with the 163.8% increase in the number of pancreas transplants performed for type 2 diabetes: 211 transplants in 2024 versus 80 in 2013 (Figure PA 34).

Over the past decade, there has been an increase in the distance between the hospital at which the deceased donor pancreas was recovered and the recipient’s transplant center. For most adult pancreas transplants, donors were still less than 50 miles from the transplant center, but this distance category decreased by 48.9% during this period: 228 transplants in 2024 versus 446 in 2013. For 50-<150 miles, there was a 14.8% decrease: 202 transplants in 2024 versus 237 in 2013. For 150-<250 miles, there was a 50.4% increase (176 transplants in 2024 versus 117 in 2013), and for 250-<500 miles, there was a 31.1% increase (118 transplants in 2024 versus 90 in 2013). The category for donors 500 or more miles from the transplant center remained relatively constant, with 97 transplants in 2024 versus 104 in 2013 (Figure PA 35). The most significant increases in distance traveled between deceased donor hospital and recipient transplant center occurred after 2019 during the COVID-19 era. Despite the increases in travel distance, the total preservation time has remained relatively constant, with most pancreata transplanted with a preservation time of less than 12 hours (Figure PA 36).

The use of lymphodepleting induction regimens continued to increase and was the dominant agent in 2024, with 91.4% of centers reporting using this strategy. Only 1.9% of centers reported using interleukin-2 receptor antibodies alone for induction and 5.4% did not use any induction therapy in 2024 (Figure PA 37). Almost all maintenance regimens at the time of transplant hospitalization discharge (95.4%) incorporated tacrolimus and a mycophenolate agent (MMF) in 2024, with 72.2% of these using steroids as well (up from 65.5% in 2023). In 2024, of the maintenance regimens using tacrolimus and MMF, 23.1% were steroid free, down from 30.6% in 2023 (Figure PA 38).

For all categories of adult pancreas transplant, most were performed in recipients without immunologic sensitivity (calculated panel-reactive antibody <1%) or with weak sensitivity (calculated panel-reactive antibody 1<20%). For PAK recipients, there were slightly higher levels of sensitization, consistent with sensitization associated with the previous kidney transplant (Figure PA 39, Figure PA 40, and Figure PA 41).

The number of centers that have performed at least one adult pancreas transplant was 111 in 2024, a number that has remained relatively stable over the past decade (Figure PA 42). In 2024, 40.6% of pancreas transplants were performed at medium-volume centers (11-24 adult transplants per year), up from 26.6% in 2023. This increase at medium-volume centers was related to a decrease in the number of transplants at large-volume centers (25 or more transplants per year), with 19.6% of transplants in 2024, down from 32.2% in 2023. The number of lower-volume centers remained relatively constant, with 34.5% of centers reporting 3-10 pancreas transplants in 2024 and 5.4% reporting 1-2 pancreas transplants in 2024 (Figure PA 44).

4 Outcomes

The 2024 Annual Data Report marks the fifth year with criteria for defining pancreas graft failure in effect. Prior to 2020, there were no definitions for pancreas graft failure, and, as a result, SRTR only reported on patient survival. Pancreas graft failure is defined by the occurrence of any of the following events: 1) a recipient’s transplanted pancreas is removed; 2) a recipient re-registers for a pancreas transplant; 3) a recipient registers for an islet transplant after undergoing a pancreas transplant; 4) a recipient dies; or 5) a recipient’s total insulin use is greater or equal to 0.5 units/kg/day for 90 consecutive days (OPTN Policy, 1.2 Definitions²). Using this definition, pancreas graft failure in adults within the first 90 days posttransplant was relatively low for transplants in 2024: 5.1%, 17.6%, and 5.9% in PAK, PTA, and SPK, respectively (Figure PA 45). The 17.6% graft loss in the PTA group represents a large increase, as it was 8.3% in 2023; in contrast, the PAK group had substantial reduction in graft loss (5.1% in 2024 versus 16.7% in 2023). Pancreas graft failure in the first 90 days is most frequently attributed to technical losses, including graft thrombosis. The increased incidence of graft thrombosis in PTA recipients is well known, in part related to their being pre-uremic and having well-functioning platelets. The low incidences of graft losses in PAK and SPK recipients in 2024 are impressive, and it will be important to follow the trends over the next decade (Figure PA 45). Similarly, the incidences of pancreas graft failure in adults within the first year posttransplant were relatively low in all categories for transplants in 2023: 16.7% for PAK, 8.3% for PTA, and 9.4% for SPK (Figure PA 46).

The benefits of a functioning pancreas transplant on the function of the simultaneously transplanted kidney are evident by the low 1-, 5-, and 10-year unadjusted kidney graft failure rates for the most recent adult cohorts available: 5.6% for transplants in 2023, 15.0% for transplants in 2019, and 29.4% for transplants in 2014, respectively (Figure PA 47). These low rates of kidney graft failure associated with a functioning pancreas reflect the normalization of hemoglobin A_1C and resultant protection from diabetic nephropathy. The merits of hemoglobin A_1C normalization with pancreas transplant are also evidenced by the low rates of death-censored kidney failure among SPK recipients in the most recent cohorts for which sufficient follow-up is available, at 1.9%, 8.5%, and 15.9% at 1, 5, and 10 years, respectively (Figure PA 48). In addition to the beneficial effects of hemoglobin A_1C normalization on preventing reoccurrence of diabetic nephropathy, the very low rates of death-censored kidney graft failure can also be attributed to the higher quality (lower kidney donor profile index) of kidneys used in SPK. The benefits of functioning pancreas transplant on protecting kidney allografts are further exemplified by the low rates of kidney graft failure following PAK. The 10-year death-censored kidney graft failure among PAK transplant recipients in 2014-2015 from time of the pancreas transplant was 13.1% with a deceased donor kidney (Figure PA 50) and 11.9% with a living donor kidney (Figure PA 52).

Despite the well-known rigors of the pancreas transplant procedure, posttransplant mortality in adults has continued to improve for all categories of pancreas transplants. Mortality at 1 year has decreased to 1.5%, 1.9%, and 3.3% for transplants in 2022-2023 from 3.3%, 2.8%, and 5.0% for transplants in 2004-2005 for PAK, PTA, and SPK, respectively (Figure PA 54). Longer-term mortality at 10 years has decreased to 27.5%, 13.1%, and 20.6% for transplants in 2014-2015 from 30.1%, 21.1%, and 24.6% for transplants in 2004-2005 for PAK, PTA, and SPK, respectively (Figure PA 56). Patient survival at 5 years after pancreas transplant was 89.9%, 91.5%, and 91.0% for 2017-2019 recipients of PAK, PTA, and SPK, respectively, further highlighting the relative safety of all categories of pancreas transplant (Figure PA 57). People undergoing pancreas transplant in 2017-2019 with type 1 diabetes had a 5-year survival rate of 91.9%, compared with 86.9% for people undergoing pancreas transplants for type 2 diabetes. Although patient survival percentages were high for both people with type 1 diabetes and people with type 2 diabetes, the slightly worse longer-term survival rates in people with type 2 diabetes likely reflects their older average age and associated higher incidence of cardiovascular morbidities (Figure PA 58).¹^,³ The 5-year patient survival among adult deceased donor pancreas transplant recipients was 89.6% for those with donation-after-brain-death donors and 89.4% for those with DCD donors (Figure PA 59).

The incidence of acute rejection by 1 year posttransplant has decreased for all adult age groups over the past decade. The acute rejection rates at 1 year for transplants in 2023 were 10.3%, 8.1%, and 5.6% for recipients aged 18-34 years, 35-49 years, and 50-64 years, respectively (Figure PA 60). The decreased incidence of rejection in the older age groups is consistent with less rigorous immune systems associated with aging, but the incidence of rejection during the first year was extremely low across all age groups in 2024. The incidence of acute rejection by 1 year posttransplant was 7.7% in pancreas transplant recipients in 2023 who received only T-cell–depleting agents and 15.4% in those receiving interleukin-2 receptor antibodies alone for induction (Figure PA 61). As reported above (Figure PA 37), the vast majority of transplant centers have evolved to using lymphodepleting agents for induction (91.4%), likely related to the efficacy in preventing rejection in the first year following pancreas transplant.

The 5-year cumulative incidence of posttransplant lymphoproliferative disorder (PTLD) was 1.3% for Epstein-Barr (EBV) antibody–positive adult recipients but 2.3% for EBV antibody–negative adult recipients for PAK transplants performed in 2013-2019 (Figure PA 62). Among adult SPK recipients, the 5-year incidence of PTLD was 0.7% for EBV antibody–positive recipients and 2.0% for EBV antibody–negative recipients during the same era (Figure PA 64). The impact of EBV status was particularly evident following PTA, with a 5-year cumulative incidence of PTLD in EBV-positive adult recipients of 0.7% versus 3.9% in EBV-negative recipients (Figure PA 63). The relatively higher frequency of PTLD in PTA recipients is likely related to the more aggressive induction and maintenance immunosuppressive regimens used to suppress the alloimmune and autoimmune systems in these patients.⁴^,⁵

5 Donations

The overall deceased donor count (adult and pediatric) for pancreas has steadily declined over the past decade to 1,131 in 2024 from 1,346 in 2013 (Figure PA 65). This is in contrast to the overall deceased donation count for all organs in the United States, which has increased. However, since pancreas donors are a highly selected group, the increase in overall donation (especially attributable to older donors and DCD donors) has not benefited pancreas transplantation. This is evident in the age distribution of pancreas donors, where less than 10% of donors were aged 40 years or older in 2024 (Figure PA 66). With the growing use of normothermic regional perfusion and improvements in preservation techniques, it remains to be seen if the utilization of pancreata from older donors will increase in the future. Most pancreas donors continued to be male (67.0% in 2024) (Figure PA 67) and White (58.3% in 2024) (Figure PA 68). Note that while the percentage of White candidates on the waiting list has decreased to 44.2% (Figure PA 5), the proportion of White pancreas donors continued to hold steady at close to 60% in 2024 and for the past several years (Figure PA 68). Most pancreas donors in 2024 had a BMI in the 18.5-<25 category (57.7%), an increase from 2018 (51.6%). There has been a corresponding decline in donors with BMI in the 25-<30 category (27.1% in 2024 versus 31.6% in 2018), while those with a BMI above 30 made up only 5.8% of donors in 2024 (Figure PA 69). There has been a slight increase in small donors by weight (<20 kg, usually pediatric): 2.2% of donors in 2024. The sharpest increase was in donors weighing 40-<70 kg (49.0% in 2024 up from 42.4% in 2023), with a decrease in donors weighing 70 kg or more (44.8% in 2024 down from 52.9% in 2023) (Figure PA 70). Cause of death in pancreas donors continued to show a downward trend in head trauma over the past decade, with a 22.5% decrease since 2013, whereas anoxia had a 73.9% increase (Figure PA 71). Note that anoxia as a cause of death has remained stagnant since 2022.

In 2024, 25.1% of all pancreata recovered for transplant were not transplanted, and this nonuse rate has remained relatively stable over the past decade (Figure PA 72). As expected, the highest nonuse rate was for pancreata from donors older than 55 years (100% in 2024). However, note that donors aged 40-54 years had a nonuse rate of 49.0% in 2024 (Figure PA 73). There were no notable trends in nonuse rates by donor sex (Figure PA 74), race and ethnicity (Figure PA 75), or by donor risk of disease transmission (Figure PA 77). Nonuse continued to be higher as BMI increased. The nonuse rate for pancreata from donors with BMI of 35 or higher has been greater than 80% for the past few years and dropped to a still high rate of 50% in 2024, although the numbers of donors in this category are too small to allow solid evidence of trends or provide clean graphical representation (Figure PA 76).

References

Amara D, Hansen KS, Kupiec-Weglinski SA, Braun HJ, Hirose R, Hilton JF, Rickels MR, Odorico JS, Stock PG. Pancreas transplantation for type 2 diabetes: A systematic review, critical gaps in the literature, and a path forward. Transplantation. 2022;106(10):1916-1934. doi:10.1097/TP.0000000000004113

Organ Procurement and Transplantation Network. OPTN Policies, effective as of October 1, 2025. Definitions, 1.2. Published online 2025. Accessed October 10, 2025. https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf

Stratta RJ, Farney AC, Orlando G, Rogers J. Pancreas transplantation for type 2 diabetes mellitus: Who and why? Curr Transpl Rep. 2015;2:149-158. doi:10.1007/s40472-015-0055-8

Stegall MD, Kim DY, Prieto M, Cohen AJ, Griffin MD, Schwab TR, Nyberg SL, Velosa JA, Gloor JM, Innocenti F, Bohorquez H, Dean PG, Carpenter HA, Leontovich ON, Sterioff S, Larson TS. Thymoglobulin induction decreases rejection in solitary pancreas transplantation. Transplantation. 2001;72(10):1671-1675. doi:10.1097/00007890-200111270-00017

Humar A, Parr E, Drangstveit MB, Kandaswamy R, Gruessner AC, Sutherland DE. Steroid withdrawal in pancreas transplant recipients. Clin Transplant. 2000;14(1):75-78. doi:10.1034/j.1399-0012.2000.140114.x

Support, Copyright, and Citation Information

This publication was produced for the U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), by Hennepin Healthcare Research Institute (HHRI) and the United Network for Organ Sharing (UNOS) under contracts HHSH75R60220C00011/HHSH75R60226C00003 and HHSH250201900001C, respectively.

This publication lists nonfederal resources in order to provide additional information to consumers. The views and content in these resources have not been formally approved by HHS or HRSA. Neither HHS nor HRSA endorses the products or services of the listed resources.

The OPTN/SRTR 2024 Annual Data Report is not copyrighted. Readers are free to duplicate and use all or part of the information contained in this publication. Data are not copyrighted and may be used without permission if appropriate citation information is provided.

Pursuant to 42 U.S.C. 1320b-10, this publication may not be reproduced, reprinted, or redistributed for a fee without specific written authorization from HHS.

Suggested Citations:

Full citation: Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2024 Annual Data Report. U.S. Department of Health and Human Services, Health Resources and Services Administration; 2026. Accessed [insert date]. https://srtr.transplant.hrsa.gov/annualdatareports
Abbreviated full citation: OPTN/SRTR 2024 Annual Data Report. HHS/HRSA; 2026. Accessed [insert date]. https://srtr.transplant.hrsa.gov/annualdatareports
Chapter citation: [Authors]. OPTN/SRTR 2024 Annual Data Report: [chapter]. Accessed [insert date]. https://srtr.transplant.hrsa.gov/annualdatareports
Chapter citation for AJT e-supplement available at amjtransplant.org: [Authors]. OPTN/SRTR 2024 Annual Data Report: [chapter]. Am J Transplant. 2026;26([issue and suppl numbers]):[page range]. [doi]

Publications based on data in this report or supplied on request must include a citation and the following statement: The data and analyses reported in the OPTN/SRTR 2024 Annual Data Report have been supplied by the United Network for Organ Sharing and Hennepin Healthcare Research Institute under contract with HHS/HRSA. The authors alone are responsible for reporting and interpreting these data; the views expressed herein are those of the authors and not necessarily those of the U.S. government.

This report is available at https://srtr.transplant.hrsa.gov/annualdatareports. Individual chapters, as well as the report as a whole, may be downloaded.

List of Figures

Figure PA 1: New adult candidates added to the pancreas transplant waiting list
Figure PA 2: All adult candidates on the pancreas transplant waiting list
Figure PA 3: Distribution of adult candidates waiting for pancreas transplant by age
Figure PA 4: Distribution of adult candidates waiting for pancreas transplant by sex
Figure PA 5: Distribution of adult candidates waiting for pancreas transplant by race and ethnicity
Figure PA 6: Distribution of adult candidates waiting for pancreas transplant by diagnosis
Figure PA 7: Distribution of adult candidates waiting for pancreas transplant by waiting time
Figure PA 8: Distribution of adult candidates waiting for pancreas transplant by BMI
Figure PA 9: Distribution of adult candidates waiting for pancreas transplant by blood type
Figure PA 10: Distribution of adult candidates waiting for pancreas transplant by intended transplant type
Figure PA 11: Distribution of adult candidates waiting for pancreas transplant by prior pancreas transplant status
Figure PA 12: Distribution of adult candidates waiting for pancreas transplant by active status
Figure PA 13: Overall deceased donor pancreas transplant rates among adult waitlist candidates
Figure PA 14: Deceased donor pancreas transplant rates among adult waitlist candidates by diagnosis
Figure PA 15: Deceased donor pancreas transplant rates among adult waitlist candidates by blood type
Figure PA 16: Deceased donor pancreas transplant rates among adult waitlist candidates by intended transplant type
Figure PA 17: Three-year outcomes for adults waiting for pancreas after kidney transplant, new listings in 2019-2021
Figure PA 18: Three-year outcomes for adults waiting for pancreas transplant alone, new listings in 2019-2021
Figure PA 19: Three-year outcomes for adults waiting for simultaneous pancreas-kidney transplant, new listings in 2019-2021
Figure PA 20: Overall pretransplant mortality rates among adult candidates waitlisted for pancreas transplant
Figure PA 21: Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by age
Figure PA 22: Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by race and ethnicity
Figure PA 23: Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by sex
Figure PA 24: Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by intended transplant type
Figure PA 25: Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant in 2024 by DSA
Figure PA 26: Percentages of deaths within 6 months after removal among adult pancreas waitlist candidates overall
Figure PA 27: Percentages of deaths within 6 months after removal among adult pancreas waitlist candidates by age
Figure PA 28: Percentages of deaths within 6 months after removal among adult pancreas waitlist candidates by intended transplant type
Figure PA 29: Overall adult pancreas transplants
Figure PA 30: Adult pancreas transplants by pancreas transplant type
Figure PA 31: Adult pancreas transplants by recipient age
Figure PA 32: Adult pancreas transplants by sex
Figure PA 33: Adult pancreas transplants by race and ethnicity
Figure PA 34: Adult pancreas transplants by diagnosis
Figure PA 35: Adult pancreas transplants by distance between donor and center
Figure PA 36: Adult pancreas transplants by total preservation time
Figure PA 37: Induction agent use in adult pancreas transplant recipients
Figure PA 38: Immunosuppression regimen use in adult pancreas transplant recipients
Figure PA 39: cPRA in adult recipients of pancreas after kidney transplant
Figure PA 40: cPRA in adult recipients of pancreas transplant alone
Figure PA 41: cPRA in adult recipients of simultaneous pancreas-kidney transplant
Figure PA 42: Number of centers performing at least one adult pancreas transplant
Figure PA 43: Annual adult pancreas transplant center volumes by percentile
Figure PA 44: Distribution of adult pancreas transplants by annual center volume
Figure PA 45: Pancreas graft failure within the first 90 days posttransplant among adult pancreas transplant recipients
Figure PA 46: Pancreas graft failure within the first year posttransplant among adult pancreas transplant recipients
Figure PA 47: Kidney graft failure among adult SPK transplant recipients
Figure PA 48: Death censored kidney graft failure among adult SPK transplant recipients
Figure PA 49: Kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant)
Figure PA 50: Death-censored kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant)
Figure PA 51: Kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant)
Figure PA 52: Death-censored kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant)
Figure PA 53: Adult recipients alive after pancreas transplant on June 30 of the year, by age at transplant
Figure PA 54: Percentages of patient deaths at 1 year among adult pancreas transplant recipients
Figure PA 55: Percentages of patient deaths at 5 years among adult pancreas transplant recipients
Figure PA 56: Percentages of patient deaths at 10 years among adult pancreas transplant recipients
Figure PA 57: Patient survival among adult deceased donor pancreas transplant recipients, 2017-2019, by transplant type
Figure PA 58: Patient survival among adult deceased donor pancreas transplant recipients, 2017-2019, by diagnosis
Figure PA 59: Patient survival among adult deceased donor pancreas transplant recipients, 2017-2019, by DBD and DCD status
Figure PA 60: Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by age
Figure PA 61: Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by induction agent
Figure PA 62: Incidence of PTLD among adult recipients of pancreas after kidney transplant by recipient EBV status at transplant, 2013-2019
Figure PA 63: Incidence of PTLD among adult recipients of pancreas transplant alone by recipient EBV status at transplant, 2013-2019
Figure PA 64: Incidence of PTLD among adult recipients of simultaneous pancreas-kidney transplant by recipient EBV status at transplant, 2013-2019
Figure PA 65: Overall deceased pancreas donor count
Figure PA 66: Distribution of deceased pancreas donors by age
Figure PA 67: Distribution of deceased pancreas donors by sex
Figure PA 68: Distribution of deceased pancreas donors by race and ethnicity
Figure PA 69: Distribution of deceased pancreas donors by donor BMI
Figure PA 70: Distribution of deceased pancreas donors by weight
Figure PA 71: Cause of death among deceased pancreas donors
Figure PA 72: Overall percentages of pancreata recovered for transplant and not transplanted
Figure PA 73: Percentages of pancreata recovered for transplant and not transplanted by donor age
Figure PA 74: Percentages of pancreata recovered for transplant and not transplanted by donor sex
Figure PA 75: Percentages of pancreata recovered for transplant and not transplanted by donor race and ethnicity
Figure PA 76: Percentages of pancreata recovered for transplant and not transplanted by donor BMI
Figure PA 77: Percentages of pancreata recovered for transplant and not transplanted, by donor risk of disease transmission

List of Tables

Table PA 1: Demographic characteristics of adults on the pancreas transplant waiting list on December 31, 2024
Table PA 2: Clinical characteristics of adults on the pancreas transplant waiting list on December 31, 2024
Table PA 3: Listing characteristics of adults on the pancreas transplant waiting list on December 31, 2024
Table PA 4: Transplant waitlist activity among adults waiting for a pancreas after kidney transplant
Table PA 5: Transplant waitlist activity among adults waiting for a pancreas transplant alone
Table PA 6: Transplant waitlist activity among adults waiting for a simultaneous pancreas-kidney transplant
Table PA 7: Removal reason among adults waiting for pancreas after kidney transplant
Table PA 8: Removal reason among adults waiting for pancreas transplant alone
Table PA 9: Removal reason among adults waiting for simultaneous pancreas-kidney transplant
Table PA 10: Demographic characteristics of adult pancreas transplant recipients, 2024
Table PA 11: Clinical characteristics of adult pancreas transplant recipients, 2024
Table PA 12: Transplant characteristics of adult pancreas transplant recipients, 2024
Table PA 13: Adult pancreas donor-recipient serology matching, 2022-2024

**New adult candidates added to the pancreas transplant waiting list.** A new candidate is one who first joined the list during the given year, without having been listed in a previous year. Previously listed candidates who underwent transplant and subsequently relisted are considered new.

Figure PA 1: New adult candidates added to the pancreas transplant waiting list. A new candidate is one who first joined the list during the given year, without having been listed in a previous year. Previously listed candidates who underwent transplant and subsequently relisted are considered new.

**All adult candidates on the pancreas transplant waiting list.** Adult candidates on the list at any time during the year. Candidates listed at more than one center are counted once per listing.

Figure PA 2: All adult candidates on the pancreas transplant waiting list. Adult candidates on the list at any time during the year. Candidates listed at more than one center are counted once per listing.

**Distribution of adult candidates waiting for pancreas transplant by age.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive candidates are included. Age is determined at the earliest of transplant, death, removal, or December 31 of the year.

Figure PA 3: Distribution of adult candidates waiting for pancreas transplant by age. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive candidates are included. Age is determined at the earliest of transplant, death, removal, or December 31 of the year.

**Distribution of adult candidates waiting for pancreas transplant by sex.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 4: Distribution of adult candidates waiting for pancreas transplant by sex. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adult candidates waiting for pancreas transplant by race and ethnicity.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 5: Distribution of adult candidates waiting for pancreas transplant by race and ethnicity. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adult candidates waiting for pancreas transplant by diagnosis.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 6: Distribution of adult candidates waiting for pancreas transplant by diagnosis. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adult candidates waiting for pancreas transplant by waiting time.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Time on the waiting list is determined at the earliest of transplant, death, removal, or December 31 of the year. Active and inactive candidates are included.

Figure PA 7: Distribution of adult candidates waiting for pancreas transplant by waiting time. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Time on the waiting list is determined at the earliest of transplant, death, removal, or December 31 of the year. Active and inactive candidates are included.

**Distribution of adult candidates waiting for pancreas transplant by BMI.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included. BMI, body mass index.

Figure PA 8: Distribution of adult candidates waiting for pancreas transplant by BMI. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included. BMI, body mass index.

**Distribution of adult candidates waiting for pancreas transplant by blood type.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 9: Distribution of adult candidates waiting for pancreas transplant by blood type. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adult candidates waiting for pancreas transplant by intended transplant type.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 10: Distribution of adult candidates waiting for pancreas transplant by intended transplant type. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adult candidates waiting for pancreas transplant by prior pancreas transplant status.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 11: Distribution of adult candidates waiting for pancreas transplant by prior pancreas transplant status. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adult candidates waiting for pancreas transplant by active status.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included. Active status is determined at the earliest of transplant, death, removal, or December 31 of the year.

Figure PA 12: Distribution of adult candidates waiting for pancreas transplant by active status. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included. Active status is determined at the earliest of transplant, death, removal, or December 31 of the year.

**Overall deceased donor pancreas transplant rates among adult waitlist candidates.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure PA 13: Overall deceased donor pancreas transplant rates among adult waitlist candidates. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Deceased donor pancreas transplant rates among adult waitlist candidates by diagnosis.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure PA 14: Deceased donor pancreas transplant rates among adult waitlist candidates by diagnosis. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Deceased donor pancreas transplant rates among adult waitlist candidates by blood type.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure PA 15: Deceased donor pancreas transplant rates among adult waitlist candidates by blood type. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Deceased donor pancreas transplant rates among adult waitlist candidates by intended transplant type.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure PA 16: Deceased donor pancreas transplant rates among adult waitlist candidates by intended transplant type. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Three-year outcomes for adults waiting for pancreas after kidney transplant, new listings in 2019-2021.** Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

Figure PA 17: Three-year outcomes for adults waiting for pancreas after kidney transplant, new listings in 2019-2021. Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

**Three-year outcomes for adults waiting for pancreas transplant alone, new listings in 2019-2021.** Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

Figure PA 18: Three-year outcomes for adults waiting for pancreas transplant alone, new listings in 2019-2021. Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

**Three-year outcomes for adults waiting for simultaneous pancreas-kidney transplant, new listings in 2019-2021.** Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

Figure PA 19: Three-year outcomes for adults waiting for simultaneous pancreas-kidney transplant, new listings in 2019-2021. Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

**Overall pretransplant mortality rates among adult candidates waitlisted for pancreas transplant.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

Figure PA 20: Overall pretransplant mortality rates among adult candidates waitlisted for pancreas transplant. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

**Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by age.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year.

Figure PA 21: Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by age. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year.

**Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by race and ethnicity.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. The Other race category is composed of Native American, Multiracial, and unreported categories.

Figure PA 22: Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by race and ethnicity. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. The Other race category is composed of Native American, Multiracial, and unreported categories.

**Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by sex.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

Figure PA 23: Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by sex. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

**Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by intended transplant type.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

Figure PA 24: Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant by intended transplant type. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

**Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant in 2024 by DSA.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. DSA, donation service area.

Figure PA 25: Pretransplant mortality rates among adult candidates waitlisted for pancreas transplant in 2024 by DSA. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. DSA, donation service area.

**Percentages of deaths within 6 months after removal among adult pancreas waitlist candidates overall.** Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

Figure PA 26: Percentages of deaths within 6 months after removal among adult pancreas waitlist candidates overall. Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

**Percentages of deaths within 6 months after removal among adult pancreas waitlist candidates by age.** Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list. Age is determined at removal.

Figure PA 27: Percentages of deaths within 6 months after removal among adult pancreas waitlist candidates by age. Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list. Age is determined at removal.

**Percentages of deaths within 6 months after removal among adult pancreas waitlist candidates by intended transplant type.** Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

Figure PA 28: Percentages of deaths within 6 months after removal among adult pancreas waitlist candidates by intended transplant type. Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

Figure PA 29: Overall adult pancreas transplants. All adult pancreas transplants, including retransplant and multiorgan.

Figure PA 30: Adult pancreas transplants by pancreas transplant type. Adult pancreas transplants, including retransplant and multiorgan.

**Adult pancreas transplants by recipient age.** Adult pancreas transplants, including retransplant and multiorgan. Age is recipient age at transplant.

Figure PA 31: Adult pancreas transplants by recipient age. Adult pancreas transplants, including retransplant and multiorgan. Age is recipient age at transplant.

Figure PA 32: Adult pancreas transplants by sex. Adult pancreas transplants, including retransplant and multiorgan.

Figure PA 33: Adult pancreas transplants by race and ethnicity. Adult pancreas transplants, including retransplant and multiorgan.

Figure PA 34: Adult pancreas transplants by diagnosis. Adult pancreas transplants, including retransplant and multiorgan.

**Adult pancreas transplants by distance between donor and center.** All adult pancreas transplants, including retransplant and multiorgan. Distance between donor and center is computed from donor hospital to the transplant center.

Figure PA 35: Adult pancreas transplants by distance between donor and center. All adult pancreas transplants, including retransplant and multiorgan. Distance between donor and center is computed from donor hospital to the transplant center.

Figure PA 36: Adult pancreas transplants by total preservation time. All adult pancreas transplants, including retransplant and multiorgan.

**Induction agent use in adult pancreas transplant recipients.** All adult pancreas transplants, including retransplant and multiorgan. Immunosuppression at transplant reported to the OPTN. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

Figure PA 37: Induction agent use in adult pancreas transplant recipients. All adult pancreas transplants, including retransplant and multiorgan. Immunosuppression at transplant reported to the OPTN. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

**Immunosuppression regimen use in adult pancreas transplant recipients.** All adult pancreas transplants, including retransplant and multiorgan. Immunosuppression regimen at transplant reported to the OPTN. MMF, all mycophenolate agents; Tac, tacrolimus.

Figure PA 38: Immunosuppression regimen use in adult pancreas transplant recipients. All adult pancreas transplants, including retransplant and multiorgan. Immunosuppression regimen at transplant reported to the OPTN. MMF, all mycophenolate agents; Tac, tacrolimus.

**cPRA in adult recipients of pancreas after kidney transplant.** All adult pancreas transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure PA 39: cPRA in adult recipients of pancreas after kidney transplant. All adult pancreas transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

**cPRA in adult recipients of pancreas transplant alone.** All adult pancreas transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure PA 40: cPRA in adult recipients of pancreas transplant alone. All adult pancreas transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

**cPRA in adult recipients of simultaneous pancreas-kidney transplant.** All adult pancreas transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure PA 41: cPRA in adult recipients of simultaneous pancreas-kidney transplant. All adult pancreas transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

**Number of centers performing at least one adult pancreas transplant.** Count of all centers that have performed at least one pancreas transplant.

Figure PA 42: Number of centers performing at least one adult pancreas transplant. Count of all centers that have performed at least one pancreas transplant.

Figure PA 43: Annual adult pancreas transplant center volumes by percentile. Annual volume data are limited to recipients aged 18 years or older.

**Distribution of adult pancreas transplants by annual center volume.** Based on annual volume data among recipients aged 18 years or older.

Figure PA 44: Distribution of adult pancreas transplants by annual center volume. Based on annual volume data among recipients aged 18 years or older.

**Pancreas graft failure within the first 90 days posttransplant among adult pancreas transplant recipients.** All-cause graft failure is identified from multiple data sources, including the OPTN Transplant Recipient Registration Form, the OPTN Transplant Recipient Follow-up Form, and death dates from the Social Security Administration. Transplants after September 30, 2024, are excluded due to insufficient follow-up. Nonrenal multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 45: Pancreas graft failure within the first 90 days posttransplant among adult pancreas transplant recipients. All-cause graft failure is identified from multiple data sources, including the OPTN Transplant Recipient Registration Form, the OPTN Transplant Recipient Follow-up Form, and death dates from the Social Security Administration. Transplants after September 30, 2024, are excluded due to insufficient follow-up. Nonrenal multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Pancreas graft failure within the first year posttransplant among adult pancreas transplant recipients.** All-cause graft failure is identified from multiple data sources, including the OPTN Transplant Recipient Registration Form, the OPTN Transplant Recipient Follow-up Form, and death dates from the Social Security Administration. Nonrenal multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 46: Pancreas graft failure within the first year posttransplant among adult pancreas transplant recipients. All-cause graft failure is identified from multiple data sources, including the OPTN Transplant Recipient Registration Form, the OPTN Transplant Recipient Follow-up Form, and death dates from the Social Security Administration. Nonrenal multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Kidney graft failure among adult SPK transplant recipients.** Estimates are unadjusted, computed using Kaplan-Meier methods. SPK transplant recipients are followed from date of transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. Nonrenal multivisceral transplants are excluded. SPK, simultaneous pancreas-kidney.

Figure PA 47: Kidney graft failure among adult SPK transplant recipients. Estimates are unadjusted, computed using Kaplan-Meier methods. SPK transplant recipients are followed from date of transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. Nonrenal multivisceral transplants are excluded. SPK, simultaneous pancreas-kidney.

**Death censored kidney graft failure among adult SPK transplant recipients.** Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. SPK transplant recipients are followed from date of transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. Nonrenal multivisceral transplants are excluded. SPK, simultaneous pancreas-kidney.

Figure PA 48: Death censored kidney graft failure among adult SPK transplant recipients. Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. SPK transplant recipients are followed from date of transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. Nonrenal multivisceral transplants are excluded. SPK, simultaneous pancreas-kidney.

**Kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant).** Estimates are unadjusted, computed using Kaplan-Meier methods. PAK transplant recipients who previously underwent deceased donor kidney transplant are followed from the date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of previous kidney or kidney-pancreas transplant are included. Multivisceral transplants are excluded. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. All time points are 2-year periods. PAK, pancreas after kidney.

Figure PA 49: Kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant). Estimates are unadjusted, computed using Kaplan-Meier methods. PAK transplant recipients who previously underwent deceased donor kidney transplant are followed from the date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of previous kidney or kidney-pancreas transplant are included. Multivisceral transplants are excluded. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. All time points are 2-year periods. PAK, pancreas after kidney.

**Death-censored kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant).** Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. PAK transplant recipients who previously underwent deceased donor kidney transplant are followed from the date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of previous kidney or kidney-pancreas transplant are included. Multivisceral transplants are excluded. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. All time points are 2-year periods. PAK, pancreas after kidney.

Figure PA 50: Death-censored kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant). Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. PAK transplant recipients who previously underwent deceased donor kidney transplant are followed from the date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of previous kidney or kidney-pancreas transplant are included. Multivisceral transplants are excluded. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. All time points are 2-year periods. PAK, pancreas after kidney.

**Kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant).** Estimates are unadjusted, computed using Kaplan-Meier methods. PAK transplant recipients who previously underwent living donor kidney transplant are followed from date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of a previous living kidney donor transplant are included. Multivisceral transplants are excluded. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. All time points are 2-year periods. PAK, pancreas after kidney.

Figure PA 51: Kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant). Estimates are unadjusted, computed using Kaplan-Meier methods. PAK transplant recipients who previously underwent living donor kidney transplant are followed from date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of a previous living kidney donor transplant are included. Multivisceral transplants are excluded. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. All time points are 2-year periods. PAK, pancreas after kidney.

**Death-censored kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant).** Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. PAK transplant recipients who previously underwent living donor kidney transplant are followed from date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of a previous living kidney donor transplant are included. Multivisceral transplants are excluded. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. All time points are 2-year periods. PAK, pancreas after kidney.

Figure PA 52: Death-censored kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant). Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. PAK transplant recipients who previously underwent living donor kidney transplant are followed from date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of a previous living kidney donor transplant are included. Multivisceral transplants are excluded. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. All time points are 2-year periods. PAK, pancreas after kidney.

**Adult recipients alive after pancreas transplant on June 30 of the year, by age at transplant.** Recipients are not censored at reported graft failure since the uniform definition of graft failure was not in effect until 2018. However, a recipient may experience a reported graft failure and be removed from the cohort, undergo retransplant, and re-enter the cohort.

Figure PA 53: Adult recipients alive after pancreas transplant on June 30 of the year, by age at transplant. Recipients are not censored at reported graft failure since the uniform definition of graft failure was not in effect until 2018. However, a recipient may experience a reported graft failure and be removed from the cohort, undergo retransplant, and re-enter the cohort.

**Percentages of patient deaths at 1 year among adult pancreas transplant recipients.** Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 1 year posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 54: Percentages of patient deaths at 1 year among adult pancreas transplant recipients. Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 1 year posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Percentages of patient deaths at 5 years among adult pancreas transplant recipients.** Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 5 years posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 55: Percentages of patient deaths at 5 years among adult pancreas transplant recipients. Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 5 years posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Percentages of patient deaths at 10 years among adult pancreas transplant recipients.** Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 10 years posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 56: Percentages of patient deaths at 10 years among adult pancreas transplant recipients. Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 10 years posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Patient survival among adult deceased donor pancreas transplant recipients, 2017-2019, by transplant type.** Patient survival estimated using unadjusted Kaplan-Meier methods. Multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 57: Patient survival among adult deceased donor pancreas transplant recipients, 2017-2019, by transplant type. Patient survival estimated using unadjusted Kaplan-Meier methods. Multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Patient survival among adult deceased donor pancreas transplant recipients, 2017-2019, by diagnosis.** Patient survival estimated using unadjusted Kaplan-Meier methods. Multivisceral transplants are excluded.

Figure PA 58: Patient survival among adult deceased donor pancreas transplant recipients, 2017-2019, by diagnosis. Patient survival estimated using unadjusted Kaplan-Meier methods. Multivisceral transplants are excluded.

**Patient survival among adult deceased donor pancreas transplant recipients, 2017-2019, by DBD and DCD status.** Patient survival estimated using unadjusted Kaplan-Meier methods. DBD, donation after brain death; DCD, donation after circulatory death.

Figure PA 59: Patient survival among adult deceased donor pancreas transplant recipients, 2017-2019, by DBD and DCD status. Patient survival estimated using unadjusted Kaplan-Meier methods. DBD, donation after brain death; DCD, donation after circulatory death.

**Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by age.** Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. Missing dots indicate no pancreata were transplanted in patients in the age category in the year. Age is recipient age at transplant.

Figure PA 60: Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by age. Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. Missing dots indicate no pancreata were transplanted in patients in the age category in the year. Age is recipient age at transplant.

**Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by induction agent.** Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

Figure PA 61: Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by induction agent. Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

**Incidence of PTLD among adult recipients of pancreas after kidney transplant by recipient EBV status at transplant, 2013-2019.** Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin's disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

Figure PA 62: Incidence of PTLD among adult recipients of pancreas after kidney transplant by recipient EBV status at transplant, 2013-2019. Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin’s disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

**Incidence of PTLD among adult recipients of pancreas transplant alone by recipient EBV status at transplant, 2013-2019.** Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin's disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

Figure PA 63: Incidence of PTLD among adult recipients of pancreas transplant alone by recipient EBV status at transplant, 2013-2019. Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin’s disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

**Incidence of PTLD among adult recipients of simultaneous pancreas-kidney transplant by recipient EBV status at transplant, 2013-2019.** Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin's disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

Figure PA 64: Incidence of PTLD among adult recipients of simultaneous pancreas-kidney transplant by recipient EBV status at transplant, 2013-2019. Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin’s disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

**Overall deceased pancreas donor count.** Count of deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

Figure PA 65: Overall deceased pancreas donor count. Count of deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

**Distribution of deceased pancreas donors by age.** Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

Figure PA 66: Distribution of deceased pancreas donors by age. Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

**Distribution of deceased pancreas donors by sex.** Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

Figure PA 67: Distribution of deceased pancreas donors by sex. Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

**Distribution of deceased pancreas donors by race and ethnicity.** Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded. The Other race category is composed of Native American, Multiracial, and unreported categories.

Figure PA 68: Distribution of deceased pancreas donors by race and ethnicity. Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded. The Other race category is composed of Native American, Multiracial, and unreported categories.

**Distribution of deceased pancreas donors by donor BMI.** Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded. BMI, body mass index.

Figure PA 69: Distribution of deceased pancreas donors by donor BMI. Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded. BMI, body mass index.

Figure PA 70: Distribution of deceased pancreas donors by weight. Deceased donors whose pancreata were recovered for transplant.

**Cause of death among deceased pancreas donors.** Donors whose pancreata were recovered for transplant. CVA, cerebrovascular accident.

Figure PA 71: Cause of death among deceased pancreas donors. Donors whose pancreata were recovered for transplant. CVA, cerebrovascular accident.

**Overall percentages of pancreata recovered for transplant and not transplanted.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded.

Figure PA 72: Overall percentages of pancreata recovered for transplant and not transplanted. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded.

**Percentages of pancreata recovered for transplant and not transplanted by donor age.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. Missing dots indicate no pancreata were recovered from donors in the age category in the year.

Figure PA 73: Percentages of pancreata recovered for transplant and not transplanted by donor age. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. Missing dots indicate no pancreata were recovered from donors in the age category in the year.

**Percentages of pancreata recovered for transplant and not transplanted by donor sex.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded.

Figure PA 74: Percentages of pancreata recovered for transplant and not transplanted by donor sex. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded.

**Percentages of pancreata recovered for transplant and not transplanted by donor race and ethnicity.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. The Other race category is composed of Native American, Multiracial, and unreported categories.

Figure PA 75: Percentages of pancreata recovered for transplant and not transplanted by donor race and ethnicity. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. The Other race category is composed of Native American, Multiracial, and unreported categories.

**Percentages of pancreata recovered for transplant and not transplanted by donor BMI.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. Missing dots indicate no pancreata were recovered from donors in the BMI category in the year. BMI, body mass index.

Figure PA 76: Percentages of pancreata recovered for transplant and not transplanted by donor BMI. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. Missing dots indicate no pancreata were recovered from donors in the BMI category in the year. BMI, body mass index.

**Percentages of pancreata recovered for transplant and not transplanted, by donor risk of disease transmission.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. "Risk factors" refers to risk criteria for acute transmission of human immunodeficiency virus, hepatitis B virus, or hepatitis C virus from the US Public Health Service Guideline.

Figure PA 77: Percentages of pancreata recovered for transplant and not transplanted, by donor risk of disease transmission. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. “Risk factors” refers to risk criteria for acute transmission of human immunodeficiency virus, hepatitis B virus, or hepatitis C virus from the US Public Health Service Guideline.

Characteristic	PAK N	PAK Percent	PTA N	PTA Percent	SPK N	SPK Percent	All N	All Percent
Age (years)
18-34 years	25	9.9	88	24.6	488	21.0	601	20.5
35-44	93	36.8	131	36.7	853	36.7	1,077	36.7
45-54	93	36.8	92	25.8	668	28.7	853	29.0
55+	42	16.6	46	12.9	318	13.7	406	13.8
Sex
Female	109	43.1	195	54.6	1,032	44.3	1,336	45.5
Male	144	56.9	162	45.4	1,295	55.7	1,601	54.5
Race and ethnicity
Asian	8	3.2	11	3.1	131	5.6	150	5.1
Black	57	22.5	61	17.1	722	31.0	840	28.6
Hispanic	56	22.1	54	15.1	478	20.5	588	20.0
Multiracial	2	0.8	4	1.1	37	1.6	43	1.5
Native American	4	1.6	2	0.6	36	1.5	42	1.4
White	124	49.0	223	62.5	908	39.0	1,255	42.7
Unreported	2	0.8	2	0.6	15	0.6	19	0.6
Body mass index
<18.5	7	2.8	14	3.9	32	1.4	53	1.8
18.5-<25	76	30.0	133	37.3	776	33.3	985	33.5
25-<30	101	39.9	130	36.4	981	42.2	1,212	41.3
30-<35	59	23.3	63	17.6	457	19.6	579	19.7
35+	10	4.0	16	4.5	81	3.5	107	3.6
Missing	0	0	1	0.3	0	0	1	0.0
Distance between candidate and center (miles)
<50 miles	167	66.0	192	53.8	1,391	59.8	1,750	59.6
50-<100	43	17.0	47	13.2	406	17.4	496	16.9
100-<150	18	7.1	28	7.8	219	9.4	265	9.0
150-<250	12	4.7	30	8.4	160	6.9	202	6.9
250+	13	5.1	57	16.0	126	5.4	196	6.7
Missing	0	0	3	0.8	25	1.1	28	1.0
All candidates
All candidates	253	100.0	357	100.0	2,327	100.0	2,937	100.0
OPTN/SRTR 2024 Annual Data Report

Characteristic	PAK N	PAK Percent	PTA N	PTA Percent	SPK N	SPK Percent	All N	All Percent
Diagnosis
Diabetes type 1	182	71.9	255	71.4	1,539	66.1	1,976	67.3
Diabetes type 2	60	23.7	34	9.5	659	28.3	753	25.6
Other/unknown	11	4.3	68	19.0	129	5.5	208	7.1
Blood type
A	96	37.9	132	37.0	682	29.3	910	31.0
AB	12	4.7	11	3.1	56	2.4	79	2.7
B	27	10.7	53	14.8	415	17.8	495	16.9
O	118	46.6	161	45.1	1,174	50.5	1,453	49.5
All candidates
All candidates	253	100.0	357	100.0	2,327	100.0	2,937	100.0
OPTN/SRTR 2024 Annual Data Report

Characteristic	PAK N	PAK Percent	PTA N	PTA Percent	SPK N	SPK Percent	All N	All Percent
Waiting time
<90 days	24	9.5	45	12.6	370	15.9	439	14.9
3-<6 months	18	7.1	28	7.8	305	13.1	351	12.0
6-<12 months	46	18.2	53	14.8	502	21.6	601	20.5
1-<2 years	55	21.7	88	24.6	609	26.2	752	25.6
2+ years	110	43.5	143	40.1	541	23.2	794	27.0
Previous transplant
No prior transplant	206	81.4	323	90.5	2,248	96.6	2,777	94.6
Prior transplant	47	18.6	34	9.5	79	3.4	160	5.4
All candidates
All candidates	253	100.0	357	100.0	2,327	100.0	2,937	100.0
OPTN/SRTR 2024 Annual Data Report

Waiting list state	2022	2023	2024
Patients at start of year	284	259	261
Patients added during year	71	111	109
Patients removed during year	96	109	117
Patients at end of year	259	261	253
OPTN/SRTR 2024 Annual Data Report

Waiting list state	2022	2023	2024
Patients at start of year	360	383	373
Patients added during year	180	180	165
Patients removed during year	157	190	181
Patients at end of year	383	373	357
OPTN/SRTR 2024 Annual Data Report

Removal reason	2022	2023	2024
Deceased donor transplant	29	25	35
Patient died	3	8	3
Patient refused transplant	3	7	4
Improved, transplant not needed	1	1	4
Too sick for transplant	16	14	18
Other	44	52	51
Changed to kidney-pancreas list	0	2	2
OPTN/SRTR 2024 Annual Data Report

Donor	Recipient	CMV	EBV	HBsAg	HCV antibody	HCV NAT
D-	R-	16.47	1.07	97.06	92.93	94.92
D-	R+	23.16	10.66	1.95	1.22	1.26
D-	R unk	0.42	0.57	0.96	1.30	1.38
D+	R-	24.11	5.35	0.04	4.32	2.29
D+	R+	33.70	77.76	0	0.15	0.11
D+	R unk	0.88	4.32	0	0.08	0
D unk	R-	0.34	0	0	0	0.04
D unk	R+	0.92	0.27	0	0	0
D unk	R unk	0	0	0	0	0
OPTN/SRTR 2024 Annual Data Report

**Table PA 10:** **Demographic characteristics of adult pancreas transplant recipients, 2024.** Pancreas transplant recipients, including retransplant and multiorgan recipients. Distance between recipient and center is computed from recipient's home zip code to the transplant center. Distance between donor and center is computed from donor hospital to the transplant center. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.
Characteristic	PAK N	PAK Percent	PTA N	PTA Percent	SPK N	SPK Percent	All N	All Percent
Recipient age (years)
18-34 years	4	8.3	12	26.7	162	22.3	178	21.7
35-49	33	68.8	15	33.3	400	54.9	448	54.6
50-64	10	20.8	17	37.8	162	22.3	189	23.0
65+	1	2.1	1	2.2	4	0.5	6	0.7
Sex
Female	17	35.4	20	44.4	310	42.6	347	42.3
Male	31	64.6	25	55.6	418	57.4	474	57.7
Race and ethnicity
Asian	3	6.2	0	0	35	4.8	38	4.6
Black	8	16.7	2	4.4	245	33.7	255	31.1
Hispanic	13	27.1	6	13.3	147	20.2	166	20.2
Multiracial	0	0	1	2.2	8	1.1	9	1.1
Native American	0	0	0	0	8	1.1	8	1.0
White	24	50.0	36	80.0	278	38.2	338	41.2
Unreported	0	0	0	0	7	1.0	7	0.9
Body mass index
<18.5	1	2.1	1	2.2	14	1.9	16	1.9
18.5-<25	14	29.2	18	40.0	294	40.4	326	39.7
25-<30	21	43.8	16	35.6	286	39.3	323	39.3
30-<35	10	20.8	5	11.1	110	15.1	125	15.2
35+	0	0	5	11.1	12	1.6	17	2.1
Missing	2	4.2	0	0	12	1.6	14	1.7
Insurance
Private	24	50.0	28	62.2	276	37.9	328	40.0
Medicare	22	45.8	13	28.9	362	49.7	397	48.4
Medicaid	1	2.1	2	4.4	75	10.3	78	9.5
Other/unknown	1	2.1	2	4.4	15	2.1	18	2.2
Distance between recipient and center (miles)
<50 miles	33	68.8	19	42.2	442	60.7	494	60.2
50-<100	5	10.4	6	13.3	123	16.9	134	16.3
100-<150	7	14.6	4	8.9	60	8.2	71	8.6
150-<250	1	2.1	4	8.9	44	6.0	49	6.0
250+	1	2.1	12	26.7	47	6.5	60	7.3
Missing	1	2.1	0	0	12	1.6	13	1.6
Distance between donor and center (miles)
<50 miles	12	25.0	7	15.6	209	28.7	228	27.8
50-<150	5	10.4	9	20.0	188	25.8	202	24.6
150-<250	10	20.8	5	11.1	161	22.1	176	21.4

**Table PA 12:** **Transplant characteristics of adult pancreas transplant recipients, 2024.** Pancreas transplant recipients, including retransplant and multiorgan recipients. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.
Characteristic	PAK N	PAK Percent	PTA N	PTA Percent	SPK N	SPK Percent	All N	All Percent
Waiting time
<1 day	1	2.1	0	0	0	0	1	0.1
1-<90 days	5	10.4	10	22.2	274	37.6	289	35.2
3-<6 months	4	8.3	9	20.0	114	15.7	127	15.5
6-<12 months	7	14.6	12	26.7	116	15.9	135	16.4
1-<2 years	12	25.0	11	24.4	134	18.4	157	19.1
2+ years	19	39.6	3	6.7	90	12.4	112	13.6
Previous transplant for recipient
No prior transplant	35	72.9	41	91.1	715	98.2	791	96.3
Prior transplant	13	27.1	4	8.9	13	1.8	30	3.7
Total preservation time
0-<8 hours	14	29.2	21	46.7	204	28.0	239	29.1
8-<12	22	45.8	13	28.9	280	38.5	315	38.4
12-<15	8	16.7	7	15.6	136	18.7	151	18.4
15+	3	6.2	3	6.7	96	13.2	102	12.4
Missing	1	2.1	1	2.2	12	1.6	14	1.7
All recipients
All recipients	48	100.0	45	100.0	728	100.0	821	100.0
OPTN/SRTR 2024 Annual Data Report